Matinas BioPharma Holdings, Inc.
(NYSE Amex Equities : MTNB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -0.35%62.981.0%$472.19m
AMGNAmgen, Inc. 0.41%241.491.3%$448.51m
BIIBBiogen, Inc. -0.22%285.501.4%$387.69m
ILMNIllumina, Inc. -0.38%324.723.5%$323.34m
VRTXVertex Pharmaceuticals, Inc. 0.14%235.831.9%$300.14m
REGNRegeneron Pharmaceuticals, Inc. 0.10%385.942.6%$230.50m
EXASEXACT Sciences Corp. -1.92%88.0624.0%$205.44m
ALXNAlexion Pharmaceuticals, Inc. 0.68%113.272.0%$195.57m
ITCIIntra-Cellular Therapies, Inc. -1.43%26.259.0%$173.00m
INCYIncyte Corp. -0.15%80.502.5%$148.96m
SRPTSarepta Therapeutics, Inc. -1.84%127.9014.6%$138.72m
ARWRArrowhead Pharmaceuticals, Inc. -1.21%56.4211.3%$132.45m
SGENSeattle Genetics, Inc. 1.25%109.006.1%$122.98m
AAgilent Technologies, Inc. 0.79%90.171.6%$113.52m
BMRNBioMarin Pharmaceutical, Inc. -0.97%88.274.3%$108.30m

Company Profile

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.